Firms

Point Nine Capital

Berlin, Germany · Berlin, DE

pointnine.com

linkedin.com

x.com

writing.pointnine.com

Point Nine is a thesis-driven early-stage venture capital firm. We’re a small equal partnership, based in Europe, investing globally in AI for the digital, physical and biological world. At any given time, each of our four partners works closely with 6-8 companies. We invest $1-10 million per company, working alongside exceptional founders to accelerate their learning, provide unfair shortcuts, and help them realize their potential. Since 2008 the partnership has invested in 10-12 early-stage startups per year; 17 of them have surpassed $100M ARR. Notable early bets include Algolia, Chainalysis, Clio, Contentful, Delivery Hero, Docplanner, Factorial, Loom, Revolut, Typeform and Zendesk.

Founded: 2011
Type: Venture capital

Funds3

Point Nine Capital Fund VII GmbH & Co. KG2025-05-022025-05-02—
Regulatory offering USD165,016,500; USD0 sold and firstsale yet tooccur at2025-05-02filing. EURconversion exactunderlyingEURunknown. Target/offering not closedfund; amount intentionallynull.
P9 VI2022-09-262022-09-26€180M
Sixth seed fund EUR180M raised/closed; announcement2022-09-26, close reported2022-09-27.
P9 V2020-09-222020-09-22€99M
Fifth fund completed raise; exact officially published EUR99,999,999, not AUM.

Team

Aleksandra Zorylo Point Nine Capital, Operating Partner	—— – —	Berlin, Germany
Pawel Chudzinski Point Nine Capital, Partner	—— – —	Berlin, Germany
Ricardo Sequerra Amram Point Nine Capital, Partner	—— – —	Berlin, Germany
Louis Coppey Point Nine Capital, Partner	—— – —	France
Christoph Janz Point Nine Capital, Partner	—— – —	Stuttgart, Germany · Berlin, Germany
Bethany D'Sylva Point Nine Capital, Senior Fund Operations Manager	—— – —
Caitlin Watson Point Nine Capital, Office Manager and Talent Acquisition	—— – —
Chaitali Sheth Point Nine Capital, Senior Legal Associate	—— – —
Florian Seemann Point Nine Capital, Research Analyst	—— – —
Kolja Hebenstreit Point Nine Capital, Venture Partner	—— – —
Laura Weritz Point Nine Capital, Director, Platform and Community	—— – —
Marco Döring Point Nine Capital, Head of Finance	—— – —
Michael Wolfe Point Nine Capital, Venture Partner	—— – —
Tilman Langer Point Nine Capital, General Counsel	—— – —

Investments

team@apexlogos.ai3 hours ago
Investment-fund research reviewed 2026-10-06. Publicly identified funds, dates, amounts and fundraising status are below. Undisclosed commitments remain unknown; this is not a complete register of private SPVs or parallel entities. Funds, sizes and status | Vehicle | Amount and status | Evidence/date | Limits | | --- | --- | --- | --- | | P9 V, fifth fund | **€99,999,999 raised** | [Firm announcement](https://writing.pointnine.com/p/bonjour-louis-boa-tarde-ricardo), 2020-09-22 | Completed raise, not target or AUM. Official published figure has no decimal cents. | | P9 VI, sixth seed fund | **€180 million raised/closed** | [Sifted](https://sifted.eu/articles/point-nine-raised-seed-fund-news), 2022-09-26; [Startbase](https://www.startbase.com/news/point-nine-schliesst-sechsten-fonds/), 2022-09-27, explicitly reports close | Latest completed fund size verified in the sources checked; do not describe it as necessarily the latest vehicle. | | Point Nine Capital Fund VII GmbH & Co. KG | **USD 165,016,500 offering amount; USD 0 sold at filing; first sale yet to occur** | [SEC Form D XML](https://www.sec.gov/Archives/edgar/data/2066605/000206660525000002/primary_doc.xml), filed 2025-05-02; [SEC issuer submissions](https://data.sec.gov/submissions/CIK0002066605.json) checked 2026-10-06 | **Target/offering, not verified close.** Filing says figures represent EUR-to-USD conversion but does not give the underlying euro amount in the amounts field. Do not infer an exact euro target. No later Form D appeared in the retrieved issuer submissions. | The Fund VII evidence materially qualifies the older fund description. The primary SEC XML was retrieved directly with a local HTTP request after the browser tool could not render the styled XML; offering amount, amount sold and first-sale status were read from the actual filing. [StreetInsider's filing reproduction](https://www.streetinsider.com/SEC+Filings/Form+D+Point+Nine+Capital+Fund/24735304.html) (2025-05-02) independently provides a readable copy. The lack of a subsequent filing or public close does not establish that Fund VII remains unclosed today. No independently verified current aggregate AUM was found; do not sum historical funds and call that AUM. Funds recorded in Adex after this review: | Fund | Disclosed amount | Announcement / filing date | | --- | --- | --- | | P9 V | EUR 99999999 | 2020-09-22 | | P9 VI | EUR 180000000 | 2022-09-26 | | Point Nine Capital Fund VII GmbH & Co. KG | Undisclosed / unverified | 2025-05-02 |
team@apexlogos.ai4 hours ago
Match research 2026-10-06 / PointNineCapital / sha256:2b4aa5b78ea3ef5c0ea9ed78439471b4792dce9eb35930f74b2c961263209f76 / part 2 of 2 Imported completed research. Baseline Adex/Signal statements describe prior state, not independent verification. Retain cited attribution, date, currency and classification caveats. | **Anthropic** | Research-intensive frontier foundation models and interpretability/reliability work; AI deep tech rather than an ordinary SaaS wrapper. | Point Nine confirms **Series G participation**. Entry involved rolling over its stake after portfolio company Vercept's acquisition and adding capital; this is partly acquisition-derived exposure and partly new investment. Dollar allocation/vehicle not disclosed. | [Firm investment explanation](https://writing.pointnine.com/p/why-we-invested-in-anthropic), 2026-05-26. | | **Forithmus** | Proprietary 3D CT/MRI datasets and end-to-end medical-imaging foundation models; see neurotech-adjacency limits below. | Point Nine **co-led first financing with e2vc**, confirmed by the firm in July 2026. KPMG records **$4 million**, March 2026, and calls the stage seed; other sources call it pre-seed. | [Firm investment explanation](https://writing.pointnine.com/p/what-hinton-got-wrong-about-ai-in), 2026-07-25; [KPMG Q1 2026 report](https://assets.kpmg.com/content/dam/kpmgsites/tr/pdf/2026/06/turkish-startup-investments-q1-2026.pdf), June 2026. | | **Mission Barns** | Animal-cell cultivation for fat used in alternative meats. | Reported Point Nine participation in **$24 million Series A**, April 2021. Reputable financing reporting supports attribution, but company/firm primary confirmation of this specific round was not recovered here. | [FinSMEs financing report](https://www.finsmes.com/2021/04/mission-barns-raises-24m-in-series-a-funding.html), 2021-04-07; [Dealroom company funding history](https://app.dealroom.co/companies/mission_barns), undated, accessed 2026-10-06. | Additional official-site leads warrant later transaction-level verification: **EraDrive**, autonomous spacecraft modules, seed 2025; **Poolside**, coding foundation models, seed 2023; **Odyssey**, AI world models, later-stage 2026. These are named portfolio exposures, not verified round amounts in this review. [Official homepage](https://www.pointnine.com/) (undated; accessed 2026-10-06). ## Neurotech and adjacent exposure **No verified neurotech investment found in the sources checked.** The searches covered Point Nine paired with neurotech, brain interfaces and neural investment terminology, the saved investment list, NFX Signal and official portfolio/strategy material. This is an evidence limit, not a claim of no such investments. **Forithmus is verified adjacency:** the company's own [LinkedIn profile](https://www.linkedin.com/company/forithmus) (undated; accessed 2026-10-06) describes MR-RATE as a brain MRI dataset/model, and its [official GitHub organization](https://github.com/forithmus) exposes medical-imaging model projects. The firm confirms investment. Its broader business reads medical images and drafts radiology reports; the sources do not establish brain interfaces, neural recording, stimulation or a specifically neurological clinical indication. Classify as **medical AI/brain-imaging adjacency**, not direct neurotech. Evidence of brain MRI does not establish clinical validation or regulatory clearance. **Intuition Robotics is unresolved attribution:** it appears in the saved Adex investment records, but the [2017 company financing release hosted by OurCrowd](https://blog.ourcrowd.com/wp-content/uploads/2017/02/IR-Funding-Release-2.10.pdf) (2017-02-14) names Terra Venture Partners, Bloomberg Beta, Maniv Mobility, iRobot and OurCrowd, not Point Nine. [2020 financing reporting](https://globalventuring.com/blog/2020/02/17/intuition-robotics-ingests-36m/) (2020-02-17) names **Capital Point**, a different investment firm. Point Nine attribution is unverified and may be a name-conflation error. Social companion AI and cognitive-computing terminology would not by themselves make the company direct neurotechnology even if ownership were confirmed. ## Conflicts, gaps and later Adex review notes 1. Keep **Fund VI €180 million closed** separate from **Fund VII USD 165,016,500 offering** and from the stale Signal €100 million figure. Verify any subsequent Fund VII close before assigning current fund size. Do not equate offering, check size or AUM. 2. Current firm website's $1–10 million range supersedes older strategy/profile figures as a current public statement, but whether it is initial or lifetime-per-company is unresolved. The snapshot's USD 3 million sweet spot has no primary confirmation here. 3. Add stage dates and separate entry stages from later follow-ons; Forithmus seed versus pre-seed differs across sources. Sensmore seed versus Series A labels in aggregators conflict; prefer the unclassified official announcement until resolved. 4. Investigate Intuition Robotics attribution versus **Capital Point**. Do not carry this as verified deep-tech or neurotech portfolio evidence merely because it is in the snapshot. 5. The official current **Odyssey** link is https://odyssey.ml/, a world-model AI lab. The saved list includes **Odyssey Therapeutics**, a different company. Review the underlying participation/source before merging or relabeling either entity. 6. Deep-tech classifications are reasoned assessments, not firm-supplied labels. Anthropic's rollover must retain its acquisition context; partner angel investments before firm formation must not automatically become Point Nine firm rounds. 7. Published deal totals do not reveal Point Nine's allocation, fund vehicle, ownership, current holding status or realized exits. Early company dates and founding/incorporation dates require separate verification. All linked sources were accessed 2026-10-06. Publication dates are supplied beside claims where recovered; undated pages are not presented as newly published evidence. Research scope was fund/stage/technical-portfolio verification, not exhaustive legal diligence or reconstruction of every investment.
team@apexlogos.ai4 hours ago
Match research 2026-10-06 / PointNineCapital / sha256:2b4aa5b78ea3ef5c0ea9ed78439471b4792dce9eb35930f74b2c961263209f76 / part 1 of 2 Imported completed research. Baseline Adex/Signal statements describe prior state, not independent verification. Retain cited attribution, date, currency and classification caveats. # Point Nine Capital (Point Nine) - **Exact Adex ID:** `PointNineCapital` - **Canonical Adex URL:** https://adex.page/firms/PointNineCapital - **Research date:** 2026-10-06 - **Status:** complete research for later Adex review; no database changes made. ## Summary and identity Point Nine is a Europe-based partnership investing globally at early stages. Its present strategy explicitly covers AI across digital, physical and biological technology; verified investments span autonomous heavy machinery, robotic manipulation, cultivated meat, crop genomics and frontier AI. Neurotechnology is not established as a specific mandate. **No verified neurotech investment found in the sources checked.** Forithmus is a verified brain-imaging-adjacent investment, described separately below. The current website specifies **$1–10 million per company**, which is an investment range, not a fund size or necessarily an initial check. Its four investment partners are Christoph Janz, Pawel Chudzinski, Louis Coppey and Ricardo Sequerra Amram. [Official homepage](https://www.pointnine.com/) (undated; accessed 2026-10-06). The snapshot records founding in 2011, whereas the official portfolio describes investment history since 2008. These can describe incorporation/firm formation versus preceding investment activity; do not silently replace one with the other. [Official portfolio](https://www.pointnine.com/companies) (undated; accessed 2026-10-06). ## Starting evidence: Adex and NFX Signal The exact-ID saved Adex MCP snapshot, `data/research/_sources/PointNineCapital.adex.json`, was retrieved 2026-10-06. It already describes the expanded AI mandate and holds a USD 1 million minimum, USD 10 million maximum and USD 3 million sweet spot. The sweet spot has not been independently verified. Its many investment records include Sereact, Sensmore, Gourmey, Mission Barns, Forithmus, Aardaia, Anthropic, Intuition Robotics and an entity named Odyssey Therapeutics. Many originated in Goldilocks aggregation, have unknown dates, or contain company-round totals rather than Point Nine's investment amounts. Preserve them as leads until evidence supports the individual attribution. No NFX URL was present in the snapshot's investor profile. A search located and directly read [Christoph Janz's NFX Signal profile](https://signal.nfx.com/investors/christoph-janz) (undated; accessed 2026-10-06). It identifies him as a Point Nine Capital partner, lists seed/pre-seed SaaS, marketplaces, developer tools and other software rankings, and shows a **€100 million “current fund”**, **$580,000–$3.5 million** investment range and **$1.5 million** sweet spot. The profile's euro fund figure conflicts with the later €180 million sixth fund and appears stale; the personal investment range also differs from the current firm website. Individual-profile investment entries are not automatically firm commitments or direct neurotech evidence. The profile was publicly readable, but detailed records/intro paths are not a substitute for financing announcements. ## Funds, sizes and status | Vehicle | Amount and status | Evidence/date | Limits | | --- | --- | --- | --- | | P9 V, fifth fund | **€99,999,999 raised** | [Firm announcement](https://writing.pointnine.com/p/bonjour-louis-boa-tarde-ricardo), 2020-09-22 | Completed raise, not target or AUM. Official published figure has no decimal cents. | | P9 VI, sixth seed fund | **€180 million raised/closed** | [Sifted](https://sifted.eu/articles/point-nine-raised-seed-fund-news), 2022-09-26; [Startbase](https://www.startbase.com/news/point-nine-schliesst-sechsten-fonds/), 2022-09-27, explicitly reports close | Latest completed fund size verified in the sources checked; do not describe it as necessarily the latest vehicle. | | Point Nine Capital Fund VII GmbH & Co. KG | **USD 165,016,500 offering amount; USD 0 sold at filing; first sale yet to occur** | [SEC Form D XML](https://www.sec.gov/Archives/edgar/data/2066605/000206660525000002/primary_doc.xml), filed 2025-05-02; [SEC issuer submissions](https://data.sec.gov/submissions/CIK0002066605.json) checked 2026-10-06 | **Target/offering, not verified close.** Filing says figures represent EUR-to-USD conversion but does not give the underlying euro amount in the amounts field. Do not infer an exact euro target. No later Form D appeared in the retrieved issuer submissions. | The Fund VII evidence materially qualifies the older fund description. The primary SEC XML was retrieved directly with a local HTTP request after the browser tool could not render the styled XML; offering amount, amount sold and first-sale status were read from the actual filing. [StreetInsider's filing reproduction](https://www.streetinsider.com/SEC+Filings/Form+D+Point+Nine+Capital+Fund/24735304.html) (2025-05-02) independently provides a readable copy. The lack of a subsequent filing or public close does not establish that Fund VII remains unclosed today. No independently verified current aggregate AUM was found; do not sum historical funds and call that AUM. ## Investment stages The 2020 firm announcement explicitly says seed is its core entry point, with occasional pre-seed, Seed II and early Series A investments, and a commitment to participate in portfolio Series A rounds. Those are historical strategy statements. The current homepage still says early-stage and shows pre-seed/seed examples, while current portfolio holdings include later-stage exposures. In its [2026-05-26 Anthropic investment explanation](https://writing.pointnine.com/p/why-we-invested-in-anthropic), Point Nine explicitly maintains its early-stage focus and characterizes this late-stage transaction as an exceptional opportunity. Historical follow-ons or Anthropic should not be converted into a general growth-stage mandate. ## Verified previous deep-tech investments The classification below is analytical: technologies depend on research, difficult engineering or biological development beyond ordinary enterprise SaaS. Round amounts are total company financing, **not Point Nine checks**. Fund vehicle and individual allocation are undisclosed unless stated. | Company | Technology rationale | Firm attribution and transaction | Supporting evidence/date | | --- | --- | --- | --- | | **Sensmore** | End-to-end physical AI and vision-language-action systems retrofit heavy mining/construction machinery for autonomous operation. | Point Nine **led $7.3 million funding**, publicly announced 2025-05-20. The official release does not explicitly label the round seed or Series A; additional public support is mentioned separately. | [Company funding announcement](https://www.sensmore.ai/press/funding-announcement), 2025-05-20. | | **Sereact** | Robotic manipulation and vision-language-action AI; the “robotic brain” is software controlling machines, not biological neurotechnology. | Point Nine is a returning investor in the **$110 million Series B**, led by Headline, announced 2026-04-27. Also participated in **€25 million Series A**, led by Creandum, January 2025. | [Company Series B announcement](https://sereact.ai/posts/series-b), 2026-04-27; [YPOG financing counsel announcement](https://www.ypog.law/hubfs/Pressemitteilungen/YPOG%20advises%20Sereact%20on%20%E2%82%AC25%20million%20Series%20A%20funding%20round.pdf), 2025-01-22. | | **Gourmey** | Animal-cell cultivation and bioprocessing for poultry meat/foie gras; biological manufacturing. | Point Nine and Air Street Capital **co-led $10 million seed**, announced 2021-07-14. | [Co-investor Partech's official announcement](https://partechpartners.com/news/gourmey-announces-10m-seed-round-upscale-cultivated-poultry-meat), 2021-07-14. Financing includes public-institution support; exact equity/debt composition is not resolved here. | | **Aardaia** | Genomic prediction, high-resolution plant-genome data and accelerated breeding to domesticate a novel protein crop; not gene editing. | Point Nine **led seed**; the firm's dated essay confirms the attribution but gives no round amount. A separate Axios report identifies a **€5 million seed** led by Point Nine with Astanor and Grey Silo. Announcement and actual closing dates need separating. | [Firm investment thesis](https://writing.pointnine.com/p/creating-a-new-protein-crop-from), 2026-07-08; [Axios funding coverage](https://www.axios.com/newsletters/axios-pro-rata-6d9a6ff8-1e4a-4006-b630-71761a7209d1), July 2026 (exact publication day not recovered). |
team@apexlogos.ai26 days ago
potentially warm intro from Milana if her Berlin trip next week goes well )
team@apexlogos.ai26 days ago
MATCH

Funds3

Team

Co-investing

Investments